Coya Licenses Worldwide rights to Exosome Engineering Technology from Carnegie Mellon

 

• Supported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable engineering of exosomes with potential to target epitope driven neurodegenerative, autoimmune and oncologic diseases;
• Exosomes are a nanometer-sized type of extracellular vesicle that can be shed from every cell in the body- Researchers have attempted to harness the exosome as a drug delivery vehicle, but techniques previously developed required the use of complex molecular biology tools or degraded the exosome’s functionality;
• This patented technology requires no genetic modifications, overcomes known limitations of exosome manipulation, and also enables tethering proteins of interest to the exosome surface and loading cargo of interest within the exosome interior;
• Data was recently presented at the 5^th Exosome Based Therapeutic Development Summit successfully engineering a surface protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) on to Regulatory T cell (Treg) exosomes to increase selective targeting to immune cells;
• EET expands Coya’s optionality for potential non-dilutive business development and strategic partnerships with companies seeking innovative drug and RNA delivery platforms that may be selectively targeted to proteins or epitopes that drive disease.

https://www.biospace.com/article/releases/coya-therapeutics-licenses-exclusive-worldwide-rights-to-exosome-engineering-technology-eet-from-carnegie-mellon-university-cmu-/